Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 93.09M P/E - EPS this Y 36.20% Ern Qtrly Grth -
Income -49.5M Forward P/E -1.96 EPS next Y 6.70% 50D Avg Chg -18.00%
Sales 654k PEG - EPS past 5Y - 200D Avg Chg -33.00%
Dividend N/A Price/Book N/A EPS next 5Y - 52W High Chg -82.00%
Recommedations 2.00 Quick Ratio 1.44 Shares Outstanding 128.43M 52W Low Chg 2.00%
Insider Own 40.11% ROA -52.33% Shares Float 66.77M Beta 0.49
Inst Own 19.15% ROE -595.47% Shares Shorted/Prior 148.45K/262.48K Price 0.73
Gross Margin 81.50% Profit Margin - Avg. Volume 510,761 Target Price 5.00
Oper. Margin -5,841.18% Earnings Date May 10 Volume 165,338 Change -2.03%
About Clene Inc.

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company also develops CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease and to provide immune support for symptom resolution. In addition, it markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.

Clene Inc. News
05/01/24 IBN Announces From Lab to Launch Podcast Featuring Clene Inc. CEO Rob Etherington
04/23/24 Bullish Clene Insiders Loaded Up On US$9.58m Of Stock
04/16/24 Evidence for Clene’s CNM-Au8® as a Treatment for Repair and Remyelination in Multiple Sclerosis Presented in the Emerging Science Session at the 2024 American Academy of Neurology Annual Meeting
03/19/24 IBN Announces First in Human Podcast Featuring Clene Inc. CEO Rob Etherington
03/15/24 Clene Announces Peer-Reviewed Publication Characterizing the Protein Corona of the Investigational Neurodegenerative Disease Drug, CNM-Au8®
03/13/24 Clene Reports Full Year 2023 Financial Results and Recent Operating Highlights
03/07/24 Clene to Present at the 36th Annual ROTH Conference
02/29/24 Clene Presents Clinical Results of CNM-Au8® 30mg Treatment From Visionary-MS Trial Long-Term Extension at Annual ACTRIMS Forum 2024
02/22/24 Clene Reports Significant Survival Benefit With CNM-Au8® Treatment in ALS EAP Compassionate Use Programs
01/24/24 Clene VISIONARY-MS Trial Data May Support CNM-Au8(R) as MS Treatment
01/10/24 Clene Announces Significant Positive Results from LTE VISIONARY-MS Trial
01/08/24 Clene Reports Significant Improvement in Vision and Cognition With CNM-Au8® Treatment in VISIONARY-MS Trial Long-Term Open Label Extension
01/03/24 Clene's Phase 2 REPAIR-PD and REPAIR-MD Trials Support Advancement to Phase 3
12/22/23 Clene Announces New Data from HEALEY ALS Platform Trial
12/21/23 Clene Reports Reduction in Biomarker Plasma Neurofilament Light (NfL) Levels and Improved Survival With CNM-Au8® Treatment From HEALEY ALS Platform Trial Long-Term Open Label Extension
12/21/23 Clene Provides Update on ALS Clinical Development Meeting With FDA
12/19/23 How Clene CNM-Au8(R) Takes Advantage of Gold Nanocrystals to Target Neurodegenerative Disorders
12/15/23 Clene Lead Drug Candidate Featured in Peer-Reviewed Publication
12/14/23 Clene Announces Peer-Reviewed Publication Describing CNM-Au8 Brain Target Engagement In Neurodegenerative Diseases
12/12/23 Clene's Long-Term Follow-Up Data Shows Significantly Improved Survival in ALS Patients
CLNN Chatroom

User Image insiderbuyingselling Posted - 21 minutes ago

$CLNN new insider selling: 10000 shares. http://insiderbuyingselling.com/?t=CLNN

User Image josh77 Posted - 9 hours ago

$CLNN Nice recovery....

User Image josh77 Posted - 10 hours ago

$CLNN May is going to be a good month!!

User Image Mulhollandr Posted - 10 hours ago

$CLNN I beat you to the punch @networknewswire ! 🤣😉

User Image NetworkNewsWire Posted - 11 hours ago

BioMedNewsBreaks – $CLNN Spotlighted in a Recent ‘From Lab to Launch’ Podcast Release https://ibn.fm/OiWGU

User Image NetworkNewsWire Posted - 11 hours ago

$CLNN Presents Findings on Phase 2 VISIONARY-MS LTE at American Academy of Neurology Annual Meeting https://ibn.fm/O6qky

User Image doogiehow Posted - 13 hours ago

$CLNN got what I was looking for on this play, and I have minimal knowledge about the company. I’m out ✌️

User Image josh77 Posted - 13 hours ago

$CLNN

User Image josh77 Posted - 13 hours ago

$CLNN Progress is progress.... Today is a higher low than yesterday. I'll take that. Small victory.

User Image Mulhollandr Posted - 13 hours ago

$CLNN https://www.globenewswire.com/news-release/2024/05/01/2873243/0/en/IBN-Announces-From-Lab-to-Launch-Podcast-Featuring-Clene-Inc-CEO-Rob-Etherington.html

User Image Takeover24 Posted - 15 hours ago

$CLNN If you have followed this stock, today's drop was very predictable. As I have repeatedly advised, unless and until we get a partnership announcement or accelerated approval, we are going to continue to see a ton of fluctuation. If you are not here for the long term, then this is not the stock for you. I don't care if the stock is at 30 cents or 50 cents in the interim (unless I am trying to add more)....all I care about is a year or 2 from now and hopefully we are 10x from here!

User Image Mulhollandr Posted - 16 hours ago

$CLNN 300k sell. This stock is not fun to watch. I’m going to look away for a bit. 👋🏻

User Image Mulhollandr Posted - 16 hours ago

$CLNN hold your damn gains for once! 🤞🏼🍀

User Image goldenegg1 Posted - 17 hours ago

$CLNN I like the fact that the Healey center covered all site costs and EDC management through philanthropic donations; Clene provided CNM-Au8 and conducted analyses. There should be more outside support as the drug is getting lots of attention. Also, the management appears to be financially disciplined and so once the price goes up over $1, I wouldn't mind another small offering to fund the phase 3, majority funded by a third party. Hopefully, the partnership is coming before the offering. This is a buy for LT.

User Image thres Posted - 18 hours ago

$BCLI $ABBV $AMLX $CLNN This article does not even mention Nurown. Funny because Nurown is the lowest hanging fruit of ALS meds and the highest on the totem pole of ALS treatments of choice. ALS patients want more than approved meds for ALS or going into clinical trials while waiting for Nurown because ALS patients know Nurown works and would be their first choice. Go Nurown!!! Nurown works!!! https://finance.yahoo.com/news/trials-watch-four-als-drugs-160250433.html

User Image josh77 Posted - 04/30/24

$CLNN "These drugs reduced the risk of relapse, but had no effect on progressive symptom worsening," Kunko told Fox News Digital.

User Image josh77 Posted - 04/30/24

$CLNN "We're very encouraged and ready to take the next step. It's going to help a lot of people."

User Image josh77 Posted - 04/30/24

$CLNN ALL IN now... ready for a great month of May!! Keep the updates coming...

User Image idyllic421 Posted - 04/30/24

$CLNN I'm back after being gone for a month

User Image SorosSonosSatoshi Posted - 04/30/24

$CLNN hey shorts..u should read clinical data on MS

User Image SorosSonosSatoshi Posted - 04/30/24

$CLNN hey shorts..bottleneck soon. We will hit 0.666 What will u do at 0.555??

User Image SorosSonosSatoshi Posted - 04/30/24

$CLNN 17 April predicted

User Image Mulhollandr Posted - 04/30/24

$ABBV $BMY $CLNN $JNJ Who’s buying?🤔

User Image Takeover24 Posted - 04/30/24

$CLNN We have 2 bites at the apple to get the share price back over a $1 before end of July. Accelerated approval for ALS or partner to fund phase 3 for MS...and we will know the outcome of both before July. If either comes through, then we should be back over a $1 (well, if it is partnership of course depending on terms). If both come through, then I would not be shocked to see this settle between $2-3 share. If I were to handicap this, I would say it is 50-50 on accelerated approval (perhaps a little less) and 70-30 on partnership. But don't think we here anything on either until June at the earliest...so until then, people can just place their bets and have fun watching these wild daily fluctuations.

User Image RyGuy5000 Posted - 04/30/24

$CLNN everyone who bought around .33 is happy. I'm slightly regretting it. Oh well. Let's keep moving

User Image LXP Posted - 04/30/24

$CLNN getting crushed in my portfolio because of other names. This one is actually helping today. Hopefully something is up. Company deserves it

User Image josh77 Posted - 04/30/24

$CLNN As much as this has fallen.... This needs to be well over .70 then $1!!

User Image VrtcIl Posted - 04/30/24

$CLNN still gaining momentum towards 1$. The long trend is supported by consistent elevated highs and elevated lows, with notable volume signaling increased buying interest. Price: 0.44 Float: 68.5M Short Float: 0.2 % 💰 Dollar Volume: 5.6K ℹ️ USA | Biotechnology

User Image doogiehow Posted - 04/30/24

$CLNN

User Image josh77 Posted - 04/30/24

$CLNN Feels different than the last run up to .50....

Analyst Ratings
HC Wainwright & Co. Buy Apr 17, 24
Benchmark Buy Mar 20, 24
HC Wainwright & Co. Buy Mar 13, 24
HC Wainwright & Co. Buy Mar 11, 24
HC Wainwright & Co. Buy Feb 22, 24
HC Wainwright & Co. Buy Dec 21, 23
HC Wainwright & Co. Buy Sep 21, 23
HC Wainwright & Co. Buy Aug 29, 23
Roth MKM Buy Aug 29, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
MATLIN DAVID J Director Director Nov 10 Buy 0.41 250,002 102,501 7,043,686 11/13/23
Stevens John Henry Director Director Jun 26 Buy 0.80 316,455 253,164 800,204 06/27/23
Etherington Robert Dee Chief Executive Offi.. Chief Executive Officer Jun 26 Buy 0.81 25,000 20,250 25,000 06/27/23
Mosca Alison Director Director Jun 16 Buy 0.80 2,394,375 1,915,500 3,238,375 06/20/23
Gay Jonathon Director Director Jun 16 Buy 0.80 105,625 84,500 105,625 06/20/23
MATLIN DAVID J Director Director Jun 16 Buy 0.80 1,500,000 1,200,000 6,793,684 06/20/23
MATLIN DAVID J Director Director Nov 02 Buy 1.01 2,871,287 2,900,000 5,293,684 11/03/22
Gay Jonathon Director Director Nov 02 Buy 1.01 990,099 1,000,000 2,154,848 11/03/22
Ugwumba Chidozie Director Director Nov 02 Buy 1.01 990,099 1,000,000 5,518,908 11/03/22
Mosca Alison Director Director Nov 02 Buy 1.01 792,079 800,000 844,000 11/03/22
Stevens John Henry Director Director Nov 02 Buy 1.01 148,515 150,000 483,749 11/03/22
MATLIN DAVID J Director Director Jun 16 Buy 2.51 149,610 375,521 2,422,397 06/21/22
Mosca Alison Director Director Jun 15 Buy 2.62 5,000 13,100 39,476 06/16/22
MATLIN DAVID J Director Director Jun 14 Buy 2.66 96,011 255,389 2,272,787 06/16/22
MATLIN DAVID J Director Director Jun 13 Buy 3.06 55,000 168,300 2,176,776 06/14/22
MATLIN DAVID J Director Director Jun 03 Buy 2.52 60,670 152,888 2,121,776 06/07/22
MATLIN DAVID J Director Director May 27 Buy 2.27 35,000 79,450 2,061,106 05/27/22
General Resonance LLC 10% Owner 10% Owner May 16 Sell 2.2 181,818 400,000 15,560,212 05/18/22
MATLIN DAVID J Director Director May 16 Buy 2.20 181,818 400,000 2,026,106 05/18/22
Glanzman Robert Chief Medical Office.. Chief Medical Officer May 16 Sell 2.03 4,717 9,576 10,564 05/18/22
Gay Jonathon Director Director May 16 Buy 2.08 10,000 20,800 68,745 05/17/22
WILCOX REED N Director Director May 02 Option 0.15 100,000 15,000 400,233 05/03/22
MATLIN DAVID J Director Director Apr 20 Buy 3.01 132,891 400,002 1,844,288 04/21/22
MATLIN DAVID J Director Director Mar 28 Buy 3.17 18,648 59,114 1,711,397 03/30/22
MATLIN DAVID J Director Director Mar 23 Buy 2.97 40,000 118,800 1,692,749 03/25/22
MATLIN DAVID J Director Director Mar 18 Buy 2.85 55,000 156,750 1,652,749 03/22/22
General Resonance LLC 10% Owner 10% Owner Feb 01 Sell 2.96 101,352 300,002 15,874,921 02/03/22
MATLIN DAVID J Director Director Feb 01 Buy 2.96 101,352 300,002 1,597,749 02/02/22
WILCOX REED N Director Director Jan 20 Option 0.15 253,000 37,950 300,233 01/20/22